(Adds details, share movement)
Oct 4 (Reuters) - Pfizer Inc , which is seeking a wider use of its multi-billion dollar vaccine Prevnar, said a late-stage study of the Prevenar 13 vaccine met the main trial goal and the data will help the company expand a European regulatory application for the vaccine.
Prevnar 13 - known as Prevenar 13 in Europe - fights pneumonia, meningitis and other diseases caused by the pneumococcus bacteria, and was approved in the United States in December 2011 for use in people aged 50 years and over.
It protects against 13 strains of the streptococcus pneumoniae, while Prevnar - one of Pfizer's top-selling products - protects against seven strains.
A competing vaccine from GlaxoSmithKline , Synflorix, protects against 10 strains of the bacteria.
Pneumonia, caused by the pneumococcal organism, is one of the biggest causes of death in older people and its incidence begins to increase after age 50.
Pfizer said Prevenar 13 met the main goal of a late-stage study by showing that the immune response to the vaccine in the 18 to 49 year old age group was not inferior when compared with the response in the 60 to 64 year group.
Pfizer's shares were up marginally at $25.40 on the New York Stock Exchange on Thursday.
(Reporting by Balaji Sridharan in Bangalore; Editing by Roshni Menon)
Keywords: PFIZER STUDY/